Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

VITAE DIAGNOSTICS INCORPORATED

NPI: 1437599164 · TORRANCE, CA 90503 · Clinical Medical Laboratory · NPI assigned 06/26/2013

$5.12M
Total Medicaid Paid
96,773
Total Claims
44,029
Beneficiaries
18
Codes Billed
2018-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialKABBANI, ISSAM (OWNER)
NPI Enumeration Date06/26/2013

Related Entities

Other providers sharing the same authorized official: KABBANI, ISSAM

ProviderCityStateTotal Paid
CTON CORPORATION TORRANCE CA $2.81M

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 4,564 $411K
2019 4,599 $406K
2020 14,176 $898K
2021 32,746 $1.47M
2022 34,979 $1.47M
2023 2,691 $149K
2024 3,018 $319K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
U0004 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r 45,467 18,189 $2.81M
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 17,528 11,114 $1.54M
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 17,376 7,239 $243K
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 11,752 4,807 $210K
81443 48 47 $105K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 2,821 2,007 $99K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 1,585 468 $55K
81408 12 12 $16K
81162 12 12 $15K
81407 12 12 $6K
81317 12 12 $6K
81435 12 12 $4K
81406 12 12 $4K
81404 12 12 $4K
86769 76 38 $3K
81405 12 12 $2K
81403 12 12 $1K
81479 Unlisted molecular pathology procedure 12 12 $0.00